Literature DB >> 18626727

Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.

Monika Ribeiro Mello de Conchon1, Juliana Lima Costa1, Mafalda Megumi Yoshinaga Novaes1, Pedro Enrique Dorlhiac-Llacer1, Dalton de Alencar Fischer Chamone1, Israel Bendit2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18626727     DOI： 10.1007/s12185-008-0131-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

1.  Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.

Authors:  Kais Hussein; Oliver Bock; Anna Seegers; Michael Flasshove; Felicitas Henneke; Guntram Buesche; Hans Heinrich Kreipe
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

2.  Insights into JAK2-V617F mutation in CML.

Authors:  Guntram Büsche; Kais Hussein; Oliver Bock; Hans Kreipe
Journal:  Lancet Oncol       Date:  2007-10       Impact factor: 41.316

3.  Insights into JAK2-V617F mutation in CML.

Authors:  Monica Bocchia; Alessandro M Vannucchi; Alessandro Gozzetti; Paola Guglielmelli; Giada Poli; Rosaria Crupi; Marzia Defina; Alberto Bosi; Lauria Francesco
Journal:  Lancet Oncol       Date:  2007-10       Impact factor: 41.316

4.  JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.

Authors:  Alwin Krämer; Andreas Reiter; Jens Kruth; Philipp Erben; Andreas Hochhaus; Martin Müller; Nicholas C P Cross; Amy V Jones; Anthony D Ho; Manfred Hensel
Journal:  Lancet Oncol       Date:  2007-07       Impact factor: 41.316

5.  Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis.

Authors:  M Bornhäuser; B Mohr; U Oelschlaegel; P Bornhäuser; S Jacki; G Ehninger; C Thiede
Journal:  Leukemia       Date:  2007-05-03       Impact factor: 11.528

6.  The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.

Authors:  Linda M Scott; Peter J Campbell; E Joanna Baxter; Tony Todd; Philip Stephens; Sarah Edkins; Richard Wooster; Michael R Stratton; P Andrew Futreal; Anthony R Green
Journal:  Blood       Date:  2005-10-15       Impact factor: 22.113

7.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321
  7 in total
  11 in total

Review 1.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 2.  Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.

Authors:  Shinsuke Mizutani; Junya Kuroda; Daisuke Shimizu; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2010-02-11       Impact factor: 2.490

3.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

4.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

5.  Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.

Authors:  Weiyi Xu; Baode Chen; Xiangmin Tong
Journal:  Int J Hematol       Date:  2013-11-30       Impact factor: 2.490

Review 6.  Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.

Authors:  Yanhua Yue; Wei Wei; Yanting Guo; Fei Wang; Weimin Dong; Yue Liu; Yan Lin; Yang Cao; Weiying Gu
Journal:  Am J Case Rep       Date:  2020-10-06

7.  A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.

Authors:  Ping Chong Bee; G G Gan; V S Nadarajan; N A Latiff; N Menaka
Journal:  Int J Hematol       Date:  2010-01-05       Impact factor: 2.490

Review 8.  Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.

Authors:  Gilbert Bader; Bernard Dreiling
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

9.  Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.

Authors:  Sang Hyuk Park; Hyun-Sook Chi; Young-Uk Cho; Seongsoo Jang; Chan-Jeoung Park; Dae-Young Kim; Je-Hwan Lee; Kyoo-Hyung Lee
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464

10.  Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up.

Authors:  Katia Borgia Barbosa Pagnano; Márcia Torresan Delamain; Mariana Munari Magnus; José Vassallo; Carmino Antonio DE Souza; Daiane DE Almeida; Irene Lorand-Metze
Journal:  Oncol Lett       Date:  2016-05-26       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.